BIOMARKER:

ROS1 positive

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	crizotinib Sensitive: A1 - Approval JTO Clin Res Rep - 2 weeks (New C3) crizotinib Sensitive : A1 JTO Clin Res Rep - 2wk	crizotinib Sensitive: A1 - Approval JTO Clin Res Rep - 2 weeks crizotinib Sensitive : A1 JTO Clin Res Rep - 2 weeks - (New C3)
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	TPX-0005 Sensitive: B - Late Trials TPX-0005 Sensitive : B	TPX-0005 Sensitive: B - Late Trials TPX-0005 Sensitive : B
ROS1 positive	Lung Cancer	ROS1 positive	Lung Cancer	lorlatinib Sensitive: C2 – Inclusion Criteria lorlatinib Sensitive : C2	lorlatinib Sensitive: C2 – Inclusion Criteria lorlatinib Sensitive : C2
ROS1 positive	Solid Tumor	ROS1 positive	Solid Tumor	TQ-B3101 Sensitive: C2 – Inclusion Criteria TQ-B3101 Sensitive : C2	TQ-B3101 Sensitive: C2 – Inclusion Criteria TQ-B3101 Sensitive : C2
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	AB-106 Sensitive: C2 – Inclusion Criteria AB-106 Sensitive : C2	AB-106 Sensitive: C2 – Inclusion Criteria AB-106 Sensitive : C2
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	brigatinib Sensitive: C2 – Inclusion Criteria brigatinib Sensitive : C2	brigatinib Sensitive: C2 – Inclusion Criteria brigatinib Sensitive : C2
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	TQ-B3101 Sensitive: C2 – Inclusion Criteria TQ-B3101 Sensitive : C2	TQ-B3101 Sensitive: C2 – Inclusion Criteria TQ-B3101 Sensitive : C2
ROS1 positive	Mesothelioma	ROS1 positive	Mesothelioma	APG-2449 Sensitive: C2 – Inclusion Criteria APG-2449 Sensitive : C2	APG-2449 Sensitive: C2 – Inclusion Criteria APG-2449 Sensitive : C2
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	APG-2449 Sensitive: C2 – Inclusion Criteria APG-2449 Sensitive : C2	APG-2449 Sensitive: C2 – Inclusion Criteria APG-2449 Sensitive : C2
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	TQ-B3139 Sensitive: C3 – Early Trials TQ-B3139 Sensitive : C3	TQ-B3139 Sensitive: C3 – Early Trials TQ-B3139 Sensitive : C3
ROS1 positive	Solid Tumor	ROS1 positive	Solid Tumor	TPX-0005 Sensitive: C3 – Early Trials TPX-0005 Sensitive : C3	TPX-0005 Sensitive: C3 – Early Trials TPX-0005 Sensitive : C3
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3